Panelist James Kenney will give his perspective on key findings from the eMAX Health October OBC Industry Trends survey of leading payers and manufacturers.
What kind of contracts are getting executed? What are the implications of the new CMS step therapy guidelines on OBCs for Part B drugs? Will these contracts become part of drug manufacturers core discount strategy? What worked and didn’t work in 2018? What is coming in the next 12-24 months?